Stock comparison
United Therapeutics
Viatris
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
VTRS
Viatris
Market cap
$19.39B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | UTHR | VTRS | Winner |
|---|---|---|---|
| Warren Buffett | 71B | 31F | UTHR |
| Benjamin Graham | 76B | 27F | UTHR |
| Philip Fisher | 76B | 18F | UTHR |
| Peter Lynch | 62C | 7F | UTHR |
| Joel Greenblatt | 46D | 0F | UTHR |
| Charlie Munger | 64C | 26F | UTHR |
| Terry Smith | 64C | 17F | UTHR |
Side-by-side metrics
| Metric | UTHR | VTRS |
|---|---|---|
| Market cap | $24.13B | $19.39B |
| P/E (TTM) | 19.2x | - |
| EV/EBIT | 15.2x | - |
| ROIC (TTM) | 18.81% | 0.16% |
| Gross margin | 86.58% | 34.4% |
| Net margin | 40.61% | -2.04% |
| Revenue CAGR 5y | 17.22% | -5.44% |
| EPS CAGR 5y | 29.84% | -69.69% |
| Debt / Equity | - | 1.0x |
| Dividend yield | 0.0% | 2.8% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
UTHR leads on
- EPS CAGR 5y29.84%vs -69.69%+143%
- Revenue CAGR 5y17.22%vs -5.44%+132%
- Net margin40.61%vs -2.04%+105%
- Debt / Equity-vs 1.0x+100%
VTRS leads on
- EV/EBIT-vs 15.2x+180%
- P/E (TTM)-vs 19.2x+129%
- Dividend yield2.8%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.